Abstract
Two recent reports in Nature provide evidence for increasingly complex "disruptive" molecular alterations that occur during prostate cancer progression. They shed light on the intricacy of genetic changes that modulate PTEN's control over the phosphoinositide 3-kinase pathway and prostate cancer progression, and identify new potential biomarkers and therapeutic targets.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Adaptor Proteins, Signal Transducing
-
Biomarkers, Tumor / genetics
-
Carrier Proteins / genetics
-
Cyclin D1 / genetics
-
Disease Progression
-
Genetic Predisposition to Disease / genetics*
-
Guanylate Kinases
-
Humans
-
Male
-
Mutation*
-
Nuclear Proteins / genetics
-
PTEN Phosphohydrolase / genetics
-
Phosphatidylinositol 3-Kinases / metabolism
-
Prostatic Neoplasms / genetics*
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology
-
Repressor Proteins / genetics
-
Signal Transduction
Substances
-
Adaptor Proteins, Signal Transducing
-
Biomarkers, Tumor
-
CCND1 protein, human
-
Carrier Proteins
-
Nuclear Proteins
-
Repressor Proteins
-
SPOP protein, human
-
Cyclin D1
-
Guanylate Kinases
-
MAGI2 protein, human
-
PTEN Phosphohydrolase